|
Market Closed -
Nasdaq
16:00:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 14.12 USD | +2.54% |
|
-2.08% | -8.49% |
| 09-30 | Jade Biosciences, Inc. - Special Call | |
| 09-30 | Jade Biosciences, Inc. Announces Preclinical Data Characterizing Jade301 | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
Biological Products | ||
Net Income | -46.98M | -127M |
D&A | - | 26K |
Operating Income | -35.54M | -114M |
EBT | -46.98M | -127M |
CAPEX | - | -196K |
Income Tax Expense | - | 58K |
Interest Expense | - | -3.6M |
Total Assets | 72.8M | 350M |
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
Operating Income | -35.54M | -114M |
Net Income | -46.98M | -127M |
EBT | -46.98M | -127M |
CAPEX | - | -196K |
D&A | - | 26K |
Income Tax Expense | - | 58K |
Interest Expense | - | -3.6M |
Total Assets | 72.8M | 350M |
- Stock Market
- Stocks
- JBIO Stock
- Financials Jade Biosciences, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
